SERPINE1 (PAI‐1) Regulation in Mechanotransduction‐Associated Cellular Senescence
Journal of Cellular Biochemistry · 2026-09 · 127 (9)
DOI: 10.1002/jcb.70123 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular Biochemistry, online erschienen am 20.09.2026. Verfasst von Intan Chairun Nisa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bioengineering, Graduate School of Engineering Science, University of Osaka, Toyonaka, Japan. Hauptthemen laut MEDLINE: Plasminogen Activator Inhibitor 1, Mechanotransduction, Cellular, Cellular Senescence. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Cellular senescence is a complex biological process characterized by irreversible cell‐cycle arrest and acquisition of the senescence‐associated secretory phenotype (SASP). Beyond biochemical stress, increasing evidence indicates that mechanical cues from the extracellular microenvironment contribute to the regulation of senescence; however, the molecular mechanisms linking mechanotransduction to senescent phenotypes remain incompletely understood. SERPINE1 (plasminogen activator inhibitor‐1, PAI‐1) has emerged as a key mechanosensitive effector induced downstream of mechanotransduction signaling pathways. In this review, we discuss SERPINE1 as both a hallmark of cellular senescence and a functional mediator linking mechanotransduction to senescence‐associated processes. Once induced, SERPINE1 contributes to cell‐cycle arrest and extracellular matrix (ECM) remodeling by inhibiting plasmin‐dependent proteolysis. The resulting ECM accumulation and matrix stiffening further enhance integrin‐dependent mechanotransduction, promoting further SERPINE1 expression and establishing a self‐reinforcing mechanobiological feedback loop. SERPINE1 also contributes to senescence‐associated inflammatory signaling, which may further support the maintenance of the senescent phenotype. Together, these findings identify SERPINE1 as a mechanistic link between mechanotransduction, ECM remodeling, and cellular senescence. Pharmacological studies using PAI‐1 inhibitors further support the biological importance of this pathway and suggest that SERPINE1 may represent a potential therapeutic target for senescence‐associated fibrotic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Bioengineering, Graduate School of Engineering Science, University of Osaka, Toyonaka, Japan.
- Biotechnology Study Program, Department of Applied Science, Faculty of Mathematics and Natural Sciences, Universitas Negeri Malang, Malang, Indonesia.
- Postgraduate School, Universitas Airlangga, Surabaya, Indonesia.
- Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Global Center for Medical Engineering and Informatics, University of Osaka, Suita, Japan.
- R3 Institute for Newly-Emerging Science Design, University of Osaka, Suita, Japan.
ORCID-Profile: Arif Nur Muhammad Ansori, Shinji Deguchi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Nisa, I. C., Chantachotikul, P., Takahata, K., Ansori, A. N. M., & Deguchi, S. (2026). SERPINE1 (PAI‐1) Regulation in Mechanotransduction‐Associated Cellular Senescence. Journal of Cellular Biochemistry, 127(9). https://doi.org/10.1002/jcb.70123
Vancouver
Nisa IC, Chantachotikul P, Takahata K, Ansori ANM, Deguchi S. SERPINE1 (PAI‐1) Regulation in Mechanotransduction‐Associated Cellular Senescence. Journal of Cellular Biochemistry. 2026;127(9). doi:10.1002/jcb.70123
BibTeX
@article{Nisa2026,
author = {Nisa, Intan Chairun and Chantachotikul, Pirawan and Takahata, Kei and Ansori, Arif Nur Muhammad and Deguchi, Shinji},
title = {SERPINE1 (PAI‐1) Regulation in Mechanotransduction‐Associated Cellular Senescence},
journal = {Journal of Cellular Biochemistry},
year = {2026},
volume = {127},
number = {9},
doi = {10.1002/jcb.70123}
}
EUVIMED